Evidence map›Paper›PMID 35972218›Full record

Trial reportDiabetes care2022

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.

Peter Rossing, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Andreas L Birkenfeld, Janet B McGill, Sylvia E Rosas, Amer Joseph, Martin Gebel and 5 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07719621 (Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D), which is not on this map. Cited by 128 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 6 pooled it
24.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07719621 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D

TypeobservationalSponsorAeterna Medical Solutions SLRan2026 to 2026Enrolled50,000ConditionsCKD - Chronic Kidney Disease, Diabetes Mellitus Type 2
3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 6 syntheses or guidelines pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025 · on this map
    Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 6 countries.

Peter RossingSteno Diabetes Center Copenhagen, Herlev, Denmark.ORCID 0000-0002-1531-4294
Stefan D AnkerDepartment of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité-Universitätsmedizin, Berlin, Germany.
Gerasimos FilippatosSchool of Medicine, National and Kapodistrian University of Athens, Department of Cardiology, Attikon University Hospital, Athens, Greece.
Bertram PittDepartment of Medicine, University of Michigan School of Medicine, Ann Arbor, MI.
Luis M RuilopeCardiorenal Translational Laboratory and Hypertension Unit, Institute of Research Imas12, Madrid, Spain.
Andreas L BirkenfeldGerman Center for Diabetes Research (DZD), München-Neuherberg, Germany.
Janet B McGillDivision of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, St. Louis, MO.
Sylvia E RosasKidney and Hypertension Unit, Joslin Diabetes Center and Harvard Medical School, Boston, MA.ORCID 0000-0002-9903-4002
Amer JosephCardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany.
Martin GebelStatistics and Data Insights, Bayer AG, Wuppertal, Germany.
Luke RobertsClinical Development, Bayer PLC, Reading, U.K.
Markus F ScheererMedical Affairs and Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.
George L BakrisDepartment of Medicine, University of Chicago Medicine, Chicago, IL.ORCID 0000-0003-1183-1267
Rajiv AgarwalRichard L. Roudebush VA Medical Center and Indiana University, Indianapolis, IN.
FIDELIO-DKD and FIGARO-DKD Investigators
Bayer (Germany) · DEDeutsches Diabetes-Zentrum e.V. · DEJoslin Diabetes Center · USUniversity of Copenhagen · DKBayer (United Kingdom) · GBCentro de Investigación en Red en Enfermedades Cardiovasculares · ESGerman Centre for Cardiovascular Research · DENational and Kapodistrian University of Athens · GRRichard L. Roudebush VA Medical Center · USUniversity of Chicago · USUniversity of Michigan · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveFinerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) were evaluated in a prespecified pooled analysis of these studies. RESEARCH DESIGN AND

methodsPatients with type 2 diabetes and urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g and estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 were randomly assigned to finerenone or placebo; SGLT2is were permitted at any time. Outcomes included cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% eGFR decline, or renal death) end points, changes in UACR and eGFR, and safety outcomes.

resultsAmong 13,026 patients, 877 (6.7%) received an SGLT2i at baseline and 1,113 (8.5%) initiated one during the trial. For the cardiovascular composite, the hazard ratios (HRs) were 0.87 (95% CI 0.79-0.96) without SGLT2i and 0.67 (95% CI 0.42-1.07) with SGLT2i. For the kidney composite, the HRs were 0.80 (95% CI 0.69-0.92) without SGLT2i and 0.42 (95% CI 0.16-1.08) with SGLT2i. Baseline SGLT2i use did not affect risk reduction for the cardiovascular or kidney composites with finerenone (Pinteraction = 0.46 and 0.29, respectively); neither did SGLT2i use concomitant with study treatment.

conclusionsBenefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesRenal Insufficiency, ChronicGlucoseHumansNaphthyridinesSodiumfinerenoneGlucoseNaphthyridinesSodium

Identifiers

PMID35972218
PMCPMC9862372
OpenAlexW4292063341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.